Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
- May 09th, 2023
- 460 views
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69.
Meanwhile, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has reported Q1 EPS of $2.94, which exceeded the consensus estimate of $0.77. This positive news has resulted in a surge in the company's stock price, with $VYGR trading at $10.36, up by 24.67% or $2.05.
In other news, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has reported a Q1 loss of $0.15 per share, which was better than the consensus loss of $0.32 per share. This has resulted in a positive trend for the company's stock price, with $YMAB trading at $8.55, up by 26.29% or $1.78.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login